|本期目录/Table of Contents|

[1]蔡猛,樊根涛,黄剑浩,等.MicroRNA在尤文肉瘤中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2022,24(1):64-68.[doi:10.3969/j.issn.1672-271X.2022.01.014]
　CAI Meng,FAN Gen-tao,HUANG Jian-hao,et al.Research progress of microRNA in Ewing’s sarcoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(1):64-68.[doi:10.3969/j.issn.1672-271X.2022.01.014]
点击复制

MicroRNA在尤文肉瘤中的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第24卷
期数:
2022年1期
页码:
64-68
栏目:
综述
出版日期:
2022-02-20

文章信息/Info

Title:
Research progress of microRNA in Ewing’s sarcoma
作者:
蔡猛; 樊根涛; 黄剑浩; 周光新
作者单位：210002南京，东南大学医学院第二临床学院(东部战区总医院)骨科(蔡猛、樊根涛、黄剑浩、周光新)
Author(s):
CAI Meng; FAN Gen-tao;  HUANG Jian-hao ;  ZHOU Guang-xin
(Department of Orthopedics, Second School of Clinical Medicine, Southeast University/General Hospital of Eastern Theater Command, PLA, Nanjing 210002, Jiangsu, China)
关键词:
尤文肉瘤; miRNA; 诊断; 预后
Keywords:
Ewing’s sarcoma;  miRNA;  diagnosis; prognosis
分类号:
R738.1
DOI:
10.3969/j.issn.1672-271X.2022.01.014
文献标志码:
A
摘要:
尤文肉瘤(ES)是一种常见于儿童和青少年的骨与软组织肿瘤。ES的治疗目前采取化疗、局部手术切除、放射治疗的联合治疗方案。但患者5年生存率最高仍只能达到75%左右。微小RNA是一种小型的非编码RNA, 在尤文肉瘤中参与了广泛的生物学过程，如增殖、侵袭、分化和凋亡等。文章主要对近年来中miRNA在尤文肉瘤中的研究进展进行综述。
Abstract:
Ewing’s sarcoma (Ewing’s sarcoma, ES) is a bone and soft tissue tumor, that is common in children and adolescents. Ewing’s sarcoma is currently treated with a combination of chemotherapy, local surgical resection and radiotherapy. However, the highest five-year survival rate of patients can only reach about 75%. MicroRNA (miRNA) is a small non-coding RNA, that participates in a wide range of biological processes in Ewing’s sarcoma, such as proliferation, invasion, differentiation and apoptosis. This manuscript reviews the research progress of miRNA in Ewing’s sarcoma in recent years to provide a new direction for the diagnosis and treatment of Ewing’s sarcoma.

参考文献/References:

[1]Li Z, Yu X, Shen J, et al. MicroRNA expression and its clinical implications in Ewing’s sarcoma[J].Cell Prolif,2015,48(1):1-6.
[2]Grünewald TGP, Cidre-Aranaz F, Surdez D, et al. Ewingsarcoma[J].Nat Rev Dis Primers,2018,4(1):5.
[3]Gaspar N, Hawkins DS, Dirksen U, et al. Ewing Sarcoma: Current Management and Future Approaches ThroughCollaboration[J].J Clin Oncol,2015,33(27):3036-3046.
[4]Baldwin P, Likhotvorik R, Baig N, et al. Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma[J].Front Oncol,2019，9:1416.
[5]Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J].Cell， 2004，116(2):281-297.
[6]Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer[J].Annu Rev Pathol，2014，9:287-314.
[7]Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy[J].Trends Mol Med，2014，20(8):460-469.
[8]Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs[J].Cell，2009，136(4):642-655.
[9]Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges[J].Nat Rev Drug Discov，2014，13(8):622-638.
[10]Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy[J].Nat Rev Genet，2016，17(5):272-283.
[11]Mosakhani N, Guled M, Leen G, et al. An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing’s sarcoma[J].J Exp Clin Cancer Res，2012，31(1):24.
[12]Liu Y, Chen G, Liu H, et al. Integrated bioinformatics analysis of miRNA expression in Ewing sarcoma and potential regulatory effects of miR-21 via targeting ALCAM/CD166[J].Artif Cells Nanomed Biotechnol，2019，47(1):2114-2122.
[13]De Vito C, Riggi N, Suvà ML, et al. Let-7a is a direct EWS-FLI-1 target implicated in Ewing’s sarcoma development[J].PLoS One，2011，6(8):e23592.
[14]Karnuth B, Dedy N, Spieker T, et al. Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion[J].PLoS One，2014，9(3):e93067.
[15]Li W, Li Y, Guo J, et al. Overexpression of miR-199b-5p inhibits Ewing’s sarcoma cell lines by targeting CCNL1[J].Mol Med Rep，2015，12(3):3359-3364.
[16]Kawano M, Tanaka K, Itonaga I, et al. c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing’s Sarcoma Cell Line[J].PLoS One，2015，10(9):e0138560.
[17]Parafioriti A, Bason C, Armiraglio E, et al. Ewing’s Sarcoma: An Analysis of miRNA Expression Profiles and Target Genes in Paraffin-Embedded Primary Tumor Tissue[J].Int J Mol Sci,2016,17(5):656.
[18]Chen J, Zhou X, Xiao Q, et al. MiR-107 suppresses cell proliferation and tube formation of Ewing sarcoma cells partly by targeting HIF-1β[J].Hum Cell, 2018,31(1):42-49.
[19]Zhou X, Chen J, Xiao Q, et al. MicroRNA-638 inhibits cell growth and tubule formation by suppressing VEGFA expression in human Ewing sarcoma cells[J].Biosci Rep,2018,38(1):BSR20171017.
[20]Roberto GM, Vieira GM, Delsin LEA, et al. MiR-708-5p is inversely associated withEWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor[J].Cancer Genet，2019，230:21-27.
[21]Roberto GM, Delsin LEA, Vieira GM, et al. ROCK1-PredictedmicroRNAs Dysregulation Contributes to Tumor Progression in Ewing Sarcoma[J].Pathol Oncol Res, 2020,26(1):133-139.
[22]De Feo A, Sciandra M, Ferracin M, et al. Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation[J].Cell Death Dis,2019,10(7):471.
[23]Qu L, Zhang W, Li J, et al. The miR-146b-5p promotes Ewing’s sarcoma cells progression via suppressing the expression of BTG2[J].Sci Prog, 2021,104(2):368504211002043.
[24]McKinsey EL, Parrish JK, Irwin AE, et al. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs[J].Oncogene,2011,30(49):4910-4920.
[25]Nakatani F, Ferracin M, Manara MC, et al. miR-34a predicts survival of Ewing’s sarcoma patients and directly influences cell chemo-sensitivity and malignancy[J].J Pathol,2012,226(5):796-805.
[26]Franzetti GA, Laud-Duval K, Bellanger D, et al. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor[J].Oncogene, 2013,32(33):3915-3921.
[27]Parrish JK, Sechler M, Winn RA, et al. The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma[J].Oncogene, 2015,34(2):257-262.
[28]Zhang Z, Huang L, Yu Z, et al. Let-7a functions as a tumor suppressor in Ewing’s sarcoma cell lines partly by targeting cyclin-dependent kinase 6[J].DNA Cell Biol, 2014,33(3):136-147.
[29]Li J, You T, Jing J. MiR-125b inhibits cell biological progression of Ewing’s sarcoma by suppressing the PI3K/Akt signalling pathway[J].Cell Prolif, 2014,47(2):152-160.
[30]Li J, You T, Jing J. MiR-125b inhibits cell biological progression of Ewing’s sarcoma by suppressing the PI3K/Akt signalling pathway[J].Cell Prolif, 2014,47(2):152-160.
[31]Kawano M, Tanaka K, Itonaga I, et al. MicroRNA-181c prevents apoptosis by targeting of FAS receptor in Ewing’s sarcoma cells[J].Cancer Cell Int,2018,18:37.
[32]Guzel Tanoglu E, Ozturk S. miR-145 suppresses epithelial-mesenchymal transition by targeting stem cells in Ewing sarcoma cells[J].Bratisl Lek Listy, 2021,122(1):71-77.
[33]Moore C, Parrish JK, Jedlicka P. MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth[J].PLoS One, 2017,12(5):e0178028.
[34]Ye C, Yu X, Liu X, et al. miR-30d inhibits cell biological progression of Ewing’s sarcoma by suppressing the MEK/ERK and PI3K/Akt pathways in vitro[J].Oncol Lett, 2018,15(4):4390-4396.
[35]Lu Q, Lu M, Li D, et al. MicroRNA34b promotes proliferation, migration and invasion of Ewing’s sarcoma cells by downregulating Notch1[J].Mol Med Rep, 2018,18(4):3577-3588.
[36]Kawano M, Tanaka K, Itonaga I, et al. MicroRNA-301a promotes cell proliferation via PTEN targeting in Ewing’s sarcoma cells[J].Int J Oncol,2016,48(4):1531-1540.
[37]Robin TP, Smith A, McKinsey E, et al. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance[J].Mol Cancer Res,2012,10(8):1098-1108.
[38]Iida K, Fukushi J, Matsumoto Y, et al. miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor[J].Cancer Cell Int,2013,13(1):21.
[39]Sciandra M, De Feo A, Parra A, et al. Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma[J].J Cell Commun Signal,2020,14(3):335-347.
[40]Ventura S, Aryee DN, Felicetti F, et al. CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling[J].Oncogene,2016,35(30):3944-3954.
[41]Marino MT, Grilli A, Baricordi C, et al. Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression[J].Ann Oncol,2014,25(10):2080-2086.
[42]Kosela-Paterczyk H, Paziewska A, Kulecka M, et al. Signatures of circulating microRNA in four sarcoma subtypes[J].J Cancer,2020,11(4):874-882.

相似文献/References:

[1]许德兵,吴凌云综述,宋 勇审校.miRNA与肺癌关系的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2014,16(01):73.
[2]梁紫君,郑娜,张雪儿,等.外泌体与非痴呆型血管性认知障碍的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(04):401.[doi:10.3969/j.issn.1672-271X.2021.04.014]
　LIANG Zi-jun,ZHENG Na,ZHANG Xue-er,et al.Research progress of exosomes and vascular cognitive impairmentno dementia[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(1):401.[doi:10.3969/j.issn.1672-271X.2021.04.014]

备注/Memo

备注/Memo:
基金项目：江苏省卫生健康委科研项目（M2020025）
更新日期/Last Update: 2022-02-21